Reprint
Free Radical Research in Cancer
Edited by
June 2020
192 pages
- ISBN978-3-03936-088-8 (Paperback)
- ISBN978-3-03936-089-5 (PDF)
This is a Reprint of the Special Issue Free Radical Research in Cancer that was published in
Biology & Life Sciences
Summary
Cancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and signalling pathways as well as transcription profiles. There are several factors which contribute to the tumor diversity and therapy response, and oxidative stress is certainly one of them. Changes in oxygen levels due to hypoxia/reoxygenation during tumor growth modulate antioxidative patterns finally supporting increased cell diversity and adaptation to stressing conditions. Additionally, cancer chemotherapy based on ROS production can also induce also adaptation. To counteract these negative effects natural products are often used for their antioxidant activities as well as photodynamic therapy supported by novel chemosensitizers. Understanding of possible pathways which can trigger antioxidant defence at a certain time during cancer development can also provide possible strategies in fighting cancer.
Format
- Paperback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Keywords
NQO1; NQO1*2; polymorphism; quinone; breast cancer; menadione; lapachone; doxorubicin; ascorbate; oxidative stress; reactive oxygen species; oxidative stress; sperm; cancer chemotherapy; antioxidant therapy; reactive oxygen species; antioxidant proteins; chemoresistance; oxaliplatin; 5-Fluorouracil; myelodysplastic syndromes; carbonylation; oxidative stress; deferasirox; ovary; calcium channel; Trolox; granulosa cell tumor; cell death; mitochondria; photodynamic therapy; singlet oxygen; nitric oxide; light; combination therapy; antioxidants; bleomycin; cancer treatment; chemotherapy-induced toxicity; cisplatin; doxorubicin; free radicals; methotrexate; oxidative stress; ozone therapy; lung cancer; cancer metabolism; reactive oxygen species (ROS); therapy resistance; new therapeutic strategies; breast cancer stem cells; 4-hydroxy-2-nonenal; extracellular matrix; NRF2; bardoxolone methyl; prostate cancer; castration-resistant prostate cancer; androgen receptor (AR), AR-V7; anti-androgen; enzalutamide; androgen deprivation therapy; oxidative stress; cancer; antioxidant; triphala; ayurveda; chemoprevention and chemotherapy; n/a